The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Share News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.00
Bid: 8.00
Ask: 10.00
Change: -1.00 (-10.00%)
Spread: 2.00 (25.00%)
Open: 9.00
High: 9.00
Low: 8.25
Prev. Close: 10.00
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: PageGroup Slumps After Profit Warning

Wed, 10th Jul 2019 10:40

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - LOSERS----------Micro Focus International, down 6.5%. Shares in the software company continued to slide after it reported a drop in revenue and maintained its annual guidance on Tuesday. Micro Focus on Tuesday also said its high-profile acquisition of Hewlett Packard's software business was still proving difficult to integrate into its existing operations, stressing it was a "complex and significant progamme of work". The stock is down 10% since the start of the week. ----------Ashtead Group, down 1.0%. Morgan Stanley cut the equipment rentals firm to Equal Weight from Overweight. ----------FTSE 250 - WINNERS----------JD Wetherspoon, up 3.2%. The pub chain said sales were higher in the year so far and its expectations for its current financial year are unchanged. Wetherspoon said its like-for-like sale were up 6.9% for the ten weeks to July 7, with total sales up 6.6% for the same period. Year-to-date, like-for-like sales were up 6.7% while total sales rose 7.4%. The company's financial year ends on July 28, on which date the company expects to have net debt of around GBP745 million. Since its financial year began, JD Wetherspoon has opened five new pubs and disposed of another nine, with no more openings planned for its current financial year. Chair Tim Martin said that "the company's expectation for our annual results is unchanged for the current financial year".----------Playtech, up 3.0%. JPMorgan started coverage on the gambling software provider with an Overweight rating. ----------FTSE 250 - LOSERS----------PageGroup, down 15%. The recruiter said it achieved gross profit growth in its first half but expects an annual operating profit at the lower end of market expectations due to "challenging" macroeconomic conditions. Page said total gross profit for the first half of 2019 was GBP433.5 million, a 9.5% increase as reported and also 9.5% at constant currency. For the second quarter alone, gross profit was GBP224.6 million, a 7.9% rise over its GBP208.2 million gross profit the year before and a 7.4% rise at constant currency. In both the second half and the second quarter, gross profit increased most sharply in the Americas, with reported growth of 21% to GBP69.1 million from GBP57.3 million in the first half and 19% to GBP36.9 million from GBP30.9 million in the second quarter. Europe, the Middle East & Africa - which accounted for 49% of the group's profit in the first half and 48% in the second quarter - also performed well with half-year reported profit growth of 9.3% to GBP213.1 million from GBP194.9 million. Despite this growth, 2019 operating profit is expected to be at the low end of market expectations due to a difficult economic environment, Page said. ----------Hays, down 6.0%. UBS cut the recruiter to Neutral from Buy, and it also suffered a read-across from PageGroup. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Redx Pharma. Shares in the cancer and fibrosis drug discovery company doubled to 14 pence after it signed a definitive agreement with Nasdaq-listed Jazz Pharmaceuticals to sell its pan-RAF inhibitor programme. As part of the agreement, Redx will receive an upfront payment of USD3.5 million in cash but is eligible to receive up to USD203 million in development, regulatory and commercial milestone payments. The next milestone is the initiation of investigational new drug studies, followed by an IND submission to the US Food & Drug Administration. Redx also is eligible for incremental tiered royalties in "mid-single digit" percentage, based on any future net sales. ----------Xeros Technology, up 32%. The water saving and effluent reduction technology firm said its patent application for microfibre filters in domestic washing machines has been published. The patent application for the device, trademarked XFiltra, can now be licenced by domestic washing machine manufacturers. The application was published by the World Intellectual Property Organization. Xeros noted that the washing of clothes made from synthetic fibres is "the single biggest source of primary microplastics released into the oceans every year", with up to 700,000 microfibres released into the environment in just one domestic wash cycle.----------OTHER MAIN MARKET AND AIM - LOSERS----------Superdry, down 0.5%. The troubled fashion retailer reduced its annual payout after reporting a swing to loss in its most recently ended financial year. The company chopped its final dividend to 2.2 pence a share from 21.3p last year, taking the full-year payout to 11.5p per share, little more than a third the 31.2p paid in its financial 2018. Superdry said its revenue for the 52 weeks to April 27 was GBP871.7 million, broadly flat compared to GBP872.0 million reported for the same period a year ago, due to "a difficult retail climate". Superdry explained that its first half performance benefited from discounting and space growth, but it saw poor performance in the second half across all channels. The company posted a loss of GBP85.4 million, compared to GBP65.3 million profit reported a year earlier, as its underlying operating margin declined by 600 basis points to 5.5% from 11.5% the year before. Despite its struggles, Jefferies started coverage on Superdry with a Buy rating.----------

More News
19 Apr 2024 16:02

IN BRIEF: Redx Pharma shareholders approve AIM delisting plans

Redx Pharma PLC - clinical-stage biotechnology company - Shareholders pass resolution by 99.75% margin at general meeting to approve cancelling shares on AIM in London. This is now expected to take place on May 1, with last day of trading on April 30. Says it remains the company's intention to provide a matched bargain facility to assist shareholders wishing to trade in shares following the AIM delisting. Says it will make further details available in "due course" on its website.

Read more
12 Apr 2024 15:35

Director dealings: Redx Pharma CEO ups stake

(Sharecast News) - Redx Pharma revealed on Friday that chief executive Lisa Anson had acquired 399,000 ordinary shares in the AIM-listed clinical-stage biopharmaceutical firm.

Read more
2 Apr 2024 16:57

LONDON MARKET CLOSE: Europe down after Easter holiday weekend

(Alliance News) - The FTSE 100 took a hit on Tuesday, after a boost from London's miners and oil firms were not enough to lift the index.

Read more
2 Apr 2024 12:15

Redx Pharma plummets on plans to delist from AIM

(Alliance News) - Redx Pharma PLC shares fell on Tuesday, after it said it intends to cancel its shares from trading on AIM in London.

Read more
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more
2 Apr 2024 10:50

AIM WINNERS & LOSERS: 88 Energy finds oil at Hickory-1; Redx to delist

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
14 Feb 2024 09:34

IN BRIEF: Redx Pharma clarifies not currently pursuing US listing

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company - Responds to a Times article published on Tuesday saying RedX is looking to list its shares in New York. Redx says it "wishes to clarify that it is not currently in any process relating to a listing in the US, nor any other jurisdiction".

Read more
7 Feb 2024 11:08

Redx Pharma shares skyrocket on deal to sell inhibitor program

(Alliance News) - Redx Pharma PLC on Wednesday said it has struck a deal to sell Kirsten rat sarcoma virus inhibitor program to Dublin-based Jazz Pharmaceuticals PLC.

Read more
7 Feb 2024 09:29

AIM WINNERS & LOSERS: Verditek falls on cash shell plans

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
15 Dec 2023 21:09

EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
18 Oct 2023 12:30

Redx Pharma looks to progress portfolio after raising GBP14.1 million

(Alliance News) - Redx Pharma PLC on Wednesday said that it has conditionally raised around GBP14.1 million by way of a subscription for 54.1 million shares at 26 pence each.

Read more
21 Aug 2023 10:29

AIM WINNERS & LOSERS: Fulcrum Utility to leave AIM as loss widens

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
21 Aug 2023 09:33

Redx Pharma says RXC007 receives orphan drug designation from US FDA

(Alliance News) - Redx Pharma PLC on Monday said its RXC007 drug has received orphan drug designation from the US Food & Drug Administration for the treatment of idiopathic pulmonary fibrosis, a condition causing breathing difficulty due to lung scarring.

Read more
21 Aug 2023 07:43

LONDON BRIEFING: Crest Nicholson lowers annual profit forecast

(Alliance News) - Stocks in London are called flat on Monday, with little in the way of economic data or company updates to reignite risk appetite.

Read more
10 Jul 2023 11:22

Redx Pharma extends term of outstanding notes with two lenders to 2024

(Alliance News) - Redx Pharma PLC on Monday said it extended the term of its outstanding convertible loan notes issued to two lenders RM Special Holdings 3 LLC, otherwise known as Redmile, and Sofinnova Crossover I SLP by a year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.